DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas

Brain Pathology

Volumn 22, Issue 1, 2012, Pages 17-25

  Schmidt, Natalie ^a   Windmann, Sonja ^a   Reifenberger, Guido ^a   Riemenschneider, Markus J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

astrocytoma; brain tumor; chromatin immunoprecipitation; glioblastoma; methylation; RASL10A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEIN; RAS RELATED PROTEIN ON CHROMOSOME 22; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 22Q; CONTROLLED STUDY; CPG ISLAND; DATA BASE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; OVERALL SURVIVAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 22; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; MIDDLE AGED; RAS PROTEINS; REGULATORY ELEMENTS, TRANSCRIPTIONAL;

EID: 83555173277     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00507.x     Document Type: Article

References (21)

1. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ, (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20: 623-631.
2. Bos JL, (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689. (Pubitemid 19213607)
3. Chen R, Yang L, Fang J, Huo L, Zhang M, Chen F, et al, (2011) RRP22: a novel neural tumor suppressor for astrocytoma. Med Oncol 2011 Jan 25. [Epub ahead of print].
4. Elam C, Hesson L, Vos MD, Eckfeld K, Ellis CA, Bell A, et al, (2005) RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res 65: 3117-3125. (Pubitemid 40524592)
5. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al, (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121-130. (Pubitemid 38656383)
6. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, et al, (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15: 6683-6693.
7. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC, Reifenberger G, (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119: 501-507.
8. Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, von Deimling A, Louis DN, (1999) Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 58: 881-885. (Pubitemid 29372842)
9. Jiang Y, Matevossian A, Huang HS, Straubhaar J, Akbarian S, (2008) Isolation of neuronal chromatin from brain tissue. BMC Neurosci 9: 42.
10. Kouzarides T, (2007) Chromatin modifications and their function. Cell 128: 693-705. (Pubitemid 46273577)
11. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al, (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
13. Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN, (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26: 583-593. (Pubitemid 46160971)
14. Newton HB, (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3: 595-614. (Pubitemid 37337101)
15. Riemenschneider MJ, Reifenberger J, Reifenberger G, (2008) Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 122: 2503-2510. (Pubitemid 351590483)
16. Sayagues JM, Tabernero MD, Maillo A, (2007) [Cytogenetic alterations in meningioma tumors and their impact on disease outcome]. Med Clin (Barc) 128: 226-232. (Pubitemid 46382315)
17. Schagger H, (2006) Tricine-SDS-PAGE. Nat Protoc 1: 16-22.
18. Schones DE, Zhao K, (2008) Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 9: 179-191. (Pubitemid 351271798)
19. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ, (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123: 2080-2086.
20. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al, (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13: 1045-1052. (Pubitemid 46340384)
21. Zucman-Rossi J, Legoix P, Thomas G, (1996) Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region. Genomics 38: 247-254. (Pubitemid 27030111)